San Diego, CA 10/14/2009 2:50:49 AM
Biotech Chart Outlook: Alnylam Pharmaceuticals (ALNY), Vanda Pharmaceuticals (VNDA)
Vanda Pharmaceuticals and Alnylam Pharmaceuticals are rated and dissected.
Alnylam Pharmaceuticals, Inc. (ALNY) and Vanda Pharmaceuticals, Inc. (VNDA) have been reviewed and forecasted from a chartist's point of view at the Small Cap Network's new biotech community page. Both companies have been discussed at great length today, Vanda more so than Alnylam. Neither appears to be particularly bullish though, as explained by the site's analysts.
Vanda Pharmaceuticals shares surged at today's open after good news was announced, though the stock has don nothing but move lower after its excessively strong open. The trading commentary explains how and why it happened, and what it may ultimate mean for VNDA owners (potential or otherwise).
Alnylam Pharmaceuticals had been in an uptrend through last week. A major support level was broken through, setting up the likelihood of a significant move lower. The outlook explains what shape such a pullback might take, and what potential investors of ALNY may need to know before taking any further action.
Investors can review the entire outlook for Vanda Pharmaceuticals, Alnylam Pharmaceuticals, and two other related names by going to: http://www.smallcapnetwork.com/s/.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world's top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics; its most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection and is partnered with Cubist and Kyowa Hakko Kirin.
About Vanda
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com.
Forward-Looking Statement: This press release may include or imply "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
SmallCapNetwork.com is not a registered investment advisers or broker/dealer. SmallCapNetwork.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for many of their securities, investing in such securities is highly speculative and carries a high degree of risk.
Contact Information:
Small Cap Network
4653 Carmel Mtn. Rd
Suite 308 #402
San Diego, CA 92130
Email: editor@smallcapnetwork.com
Source: Small Cap Network
